Nvidia-backed AI drug developer Iambic seeks US IPO

The listing is a test of whether public markets will price AI-native drug discovery as a distinct category or simply as biotech with a compute story attached. Nvidia's presence as a shareholder gives the deal a recognizable anchor, but the raise size and implied valuation suggest this is a modest float rather than a landmark offering. What matters next is whether the pricing range holds through bookbuilding and whether the AI angle draws a durable institutional base, or whether the shares trade on clinical timelines like any other early-stage developer.